China’s Wuxi Pharma looks for $150m dose in senior
New York-listed Chinese medical technology provider Wuxi Pharmatech is cooking up a $150m dual tranche loan with one mandated lead arranger and bookrunner.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts